c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Found 128 products of "c-Met/HGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
PHA-665752
CAS:<p>PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.</p>Formula:C32H34Cl2N4O4SPurity:97.05% - 98.82%Color and Shape:SolidMolecular weight:641.61Capmatinib
CAS:<p>Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Formula:C23H17FN6OPurity:99.24%Color and Shape:SolidMolecular weight:412.42PF-04217903
CAS:<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Formula:C19H16N8OPurity:98.41% - 98.55%Color and Shape:SolidMolecular weight:372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:<p>SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).</p>Formula:C25H23FN8O2S2·HClPurity:97.95%Color and Shape:SolidMolecular weight:587JNJ-38877605
CAS:<p>JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.</p>Formula:C19H13F2N7Purity:97.04% - 98.27%Color and Shape:SolidMolecular weight:377.35Merestinib
CAS:<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Formula:C30H22F2N6O3Purity:95% - 99.71%Color and Shape:SolidMolecular weight:552.53MGCD-265 analog
CAS:<p>Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.</p>Formula:C26H20FN5O2S2Purity:98.06% - 98.68%Color and Shape:SolidMolecular weight:517.6Savolitinib
CAS:<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Formula:C17H15N9Purity:98.12%Color and Shape:SolidMolecular weight:345.36Capmatinib xHCl
CAS:<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Formula:C23H18ClFN6OPurity:98.62% - 99.81%Color and Shape:SolidMolecular weight:448.89SRI 31215 TFA
CAS:<p>SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.</p>Formula:C27H34F3N5O3Purity:98.25% - 99.97%Color and Shape:SolidMolecular weight:533.6Cabozantinib
CAS:<p>Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).</p>Formula:C28H24FN3O5Purity:99.68% - 99.88%Color and Shape:SolidMolecular weight:501.51(Z)-Semaxinib
CAS:<p>(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for</p>Formula:C15H14N2OPurity:98.82% - ≥95%Color and Shape:SolidMolecular weight:238.28Cabozantinib hydrochloride
CAS:<p>Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6</p>Formula:C28H25ClFN3O5Purity:99.97%Color and Shape:SolidMolecular weight:537.96BAY-474
CAS:<p>BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe</p>Formula:C17H15N5Purity:98.98%Color and Shape:SolidMolecular weight:289.33Afatinib
CAS:<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Formula:C24H25ClFN5O3Purity:98.56% - 99.9%Color and Shape:Off-White SolidMolecular weight:485.94Amivantamab
CAS:<p>Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.</p>Purity:97.24% (SEC-HPLC) - 99.74%Color and Shape:LiquidMolecular weight:145.88 kDaFiclatuzumab
CAS:<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Purity:95%Color and Shape:LiquidDavutamig
CAS:<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Purity:98%Color and Shape:LiquidBafisontamab
CAS:<p>Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].</p>Color and Shape:LiquidMAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Formula:C20H11Cl2N3OPurity:98%Color and Shape:SolidMolecular weight:380.23
